100944-14-7 Usage
Description
(1S,4S)-2,5-Diazabicyclo[2.2.1]heptane dihydrobromide, also known as DHβE, is a chemical compound with significant pharmaceutical potential. It is recognized as a potent and selective antagonist of the α4β2 nicotinic acetylcholine receptor, which is pivotal in nicotine addiction. DHβE's unique properties have positioned it as a candidate for smoking cessation therapies and as a valuable tool in neuroscience research, aiding in the comprehension of the nicotinic acetylcholine receptors' role in a spectrum of physiological and pathological states. Additionally, it has been explored for its analgesic properties and as a treatment for nicotine dependence, making it a versatile compound in both clinical and research settings.
Uses
Used in Smoking Cessation Therapies:
DHβE is utilized as a therapeutic agent for smoking cessation, capitalizing on its antagonistic effect on the α4β2 nicotinic acetylcholine receptor to reduce nicotine cravings and support individuals in their efforts to quit smoking.
Used in Neuroscience Research:
In the field of neuroscience, DHβE serves as a research tool to investigate the functions and implications of nicotinic acetylcholine receptors in various conditions. It aids in understanding the receptor's involvement in behavior and neurochemistry, thereby contributing to the advancement of knowledge in this domain.
Used in Analgesic Development:
DHβE is explored for its potential as an analgesic, leveraging its pharmacological properties to manage pain. The research into its efficacy and safety in this application could lead to new options for pain management.
Used in Treatment of Nicotine Dependence:
As a treatment for nicotine dependence, DHβE is applied to help individuals overcome addiction by interfering with the receptor mechanisms that contribute to the reinforcing effects of nicotine.
Used in Pharmaceutical Development:
In the pharmaceutical industry, DHβE is a subject of research and development for the creation of new medications targeting nicotine addiction and potentially other conditions related to the nicotinic acetylcholine receptors' function.
Check Digit Verification of cas no
The CAS Registry Mumber 100944-14-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,9,4 and 4 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 100944-14:
(8*1)+(7*0)+(6*0)+(5*9)+(4*4)+(3*4)+(2*1)+(1*4)=87
87 % 10 = 7
So 100944-14-7 is a valid CAS Registry Number.
100944-14-7Relevant articles and documents
Synthesis of novel derivatives of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane and their evaluation as potential ligands in asymmetric catalysis
Melgar-Fernandez, Roberto,Gonzalez-Olvera, Rodrigo,Olivares-Romero, J. Luis,Gonzalez-Lopez, Vianney,Romero-Ponce, Leticia,Ramirez-Zarate, Maria Del Refugio,Demare, Patricia,Regla, Ignacio,Juaristi, Eusebio
, p. 655 - 672 (2008/09/17)
Thirty-seven (most of them novel) chiral derivatives of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane (2-36, 38, 39) were prepared from (S)-trans-4-hydroxyproline. A selection of these chiral ligands were examined as potential ligands in the preparation of catalysts for the enantioselective addition of diethylzinc to aldehydes and as chiral Lewis acid activators in the asymmetric Diels-Alder reaction. In the former system, diamine 30 induced up to 92 % enantiomeric excess in the formation of (S)-phenyl ethyl carbinol, whereas in the case of the cycloaddition reaction between cyclopentadiene and 3-acryloyloxazolidin-2-one the catalytic complex formed between dimeric derivative 8 and copper triflate [Cu(OTf)2] afforded the expected product in a 95:5 endo/exo ratio and up to 72 % ee for the major diastereomeric product. Finally, some of the novel chiral diamines prepared in this work were also evaluated as potential organocatalysts in the asymmetric amination of ethyl α-phenyl-α-cyano acetate. Bifunctional derivative 12 provided the animated product in excellent yield and with up to 40 % ee. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.
